CRISPR Therapeutics AG
CRSP
Kedudukan dalam Saham
#3562
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering... CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
Harga Saham
$50.05
Modal Pasaran
$4.84B
Perubahan (1 hari)
0.01%
Perubahan (1 tahun)
-32.34%
Negara
CH
Perdagangan CRISPR Therapeutics AG (CRSP)
Kategori
Healthcare
Nisbah P/E bagi CRISPR Therapeutics AG (CRSP)
Nisbah P/E pada October 2026 TTM: -10.55
Menurut laporan kewangan dan harga saham terkini CRISPR Therapeutics AG, nisbah P/E semasa (TTM) ialah -10.55. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak -32.28.
Sejarah nisbah P/E bagi CRISPR Therapeutics AG dari 2014 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | -10.55 | 16.32% |
| 2024 | -9.07 | -71.92% |
| 2023 | -32.28 | 564.18% |
| 2022 | -4.86 | -131.90% |
| 2021 | 15.24 | -152.65% |
| 2020 | -28.94 | -158.41% |
| 2019 | 49.55 | -696.60% |
| 2018 | -8.31 | -39.51% |
| 2017 | -13.73 | 28.29% |
| 2016 | -10.70 | -33.03% |
| 2015 | -15.98 | -73.67% |
| 2014 | -60.71 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 28.78 | -372.80% |
US
|
|
| -28.36 | 168.79% |
US
|
|
| -24.57 | 132.85% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -387.48% |
NL
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.